Xeris Biopharma Holdings, Inc. (XERS)

Market Cap	559.06M
Revenue (ttm)	187.36M
Net Income (ttm)	-63.11M
Shares Out	149.08M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,293,477
Open	4.010
Previous Close	3.970
Day's Range	3.690 - 4.010
52-Week Range	1.690 - 4.100
Beta	1.23
Analysts	Strong Buy
Price Target	5.15 (+37.33%)
Earnings Date	Mar 5, 2025

About XERS

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 377
• Stock Exchange: NASDAQ
• Ticker Symbol: XERS
• Website: https://www.xerispharma.com

Financial Performance

In 2023, Xeris Biopharma Holdings's revenue was $163.91 million, an increase of 48.68% compared to the previous year's $110.25 million. Losses were -$62.26 million, -34.23% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is $5.15, which is an increase of 37.33% from the latest price.

Price Target

$5.15

(37.33% upside)

Analyst Consensus: Strong Buy